Good AI Capital

Aether Bio is a technology company that focuses on re-purposing enzymes to create new compounds using machine learning. By integrating machine learning with high-throughput robotic laboratories, Aether Bio engineers enzymes rapidly and enables massively parallelized experimentation. This innovative approach generates significantly larger datasets compared to competitors, allowing researchers to manufacture complex and novel products more efficiently and at a lower cost. The company's technology aims to provide healthcare institutions with sustainable and affordable chemicals and materials essential for their operations.

Serve Robotics is a company focused on developing self-driving robotic carriers tailored for last-mile delivery services, particularly in the food sector. Its flagship product is a zero-emission robot designed to operate in public spaces, enhancing the delivery experience for customers. The company leverages an advanced AI-robotics mobility platform to facilitate efficient delivery operations in urban environments. Additionally, Serve Robotics collaborates with various platforms and merchants, enabling local businesses to expand their reach and connect with more customers through innovative robotic solutions.

Pragma Bio is a biotechnology company that focuses on developing microbiome-based therapeutics for cancer and autoimmune diseases. Founded in 2018 in Millbrae, California, by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti, the company utilizes proprietary genomic sequencing, artificial intelligence, and synthetic biology techniques to discover biomarkers and therapeutics for complex immunologic disorders. Pragma Bio's platform aggregates both public and private data to create a comprehensive microbiome database, enhancing the ability to identify connections between diverse biological data. This approach not only aids in the discovery of novel biomarkers for patient risk stratification and clinical outcome prediction but also enables the identification of small molecules derived from human-associated bacteria. By leveraging real-world data and advanced analytical processes, Pragma Bio aims to streamline drug discovery and deliver innovative medicines more efficiently and cost-effectively, particularly in relation to the gut-immune axis.

Stellic Inc. is an innovative company that operates an integrated planning and advising platform aimed at enhancing the academic experience for students. The platform features tools such as Degree Planner, which assists students in selecting courses and planning their semesters, while also providing features like prerequisite checks and integrated calendars. Additionally, the Degree Audit tool helps students track their academic progress by calculating completed, in-progress, and remaining requirements. The Advisor Tool empowers advisors to identify at-risk students early on, facilitating timely interventions. Furthermore, Stellic offers Data Reports that provide university administrators with insights into course demand, student performance challenges, and overall engagement. Founded by Carnegie Mellon undergraduates, the company emerged from a desire to improve the degree planning process, and it has since garnered recognition within the academic community. Stellic Inc. is headquartered in Doha, Qatar, with an additional location in Palo Alto, California.

Bit.bio is a synthetic biology company focused on revolutionizing the production and utilization of consistent and functional human cells. Their mission is to enhance health outcomes by applying computational principles to biological processes, specifically through their patented opti-ox™ technology. This innovative approach allows for the reprogramming of human induced pluripotent stem cells into precise and mature cell types. By providing scalable and reliable batches of human cells, Bit.bio aims to improve research, facilitate drug discovery, and foster the development of advanced cell and tissue therapies. The company has assembled a team of experts in stem cells, cellular reprogramming, and mathematical modeling, emphasizing collaboration and ambition to drive their goals forward. Through their efforts, Bit.bio seeks to democratize access to vital cellular resources, ultimately transforming the landscape of medicine.

Mekonos Inc. is a biotechnology company founded in 2017 and based in San Francisco, California, specializing in the design, development, and production of gene and cell therapies. The company has created a proprietary cell-engineering platform that utilizes a silicon chip automated architecture to advance the field of genome editing. This innovative system-on-a-chip technology allows for the precise control of individual nanoneedles to inject single cells in a parallel architecture, enabling the industrial-scale production of engineered therapies for a range of genetic diseases, including cancers. Mekonos aims to provide healthcare providers with a reliable and reusable manufacturing system that can deliver various therapeutic molecules across different primary cell types, thus enhancing drug discovery and development processes.

Playco Global, Inc. is a gaming company that specializes in developing an instant-play gaming platform, enabling multiplayer experiences accessible to billions of users without the need for downloads. Founded in 2010 and based in Mountain View, California, with additional offices in San Francisco, Tokyo, and Seoul, Playco has created a browser-based streaming game engine that allows users to enjoy advanced games across various gaming platforms. The company collaborates with a wide range of partners, from major tech and social media companies to emerging startups, to develop innovative gaming technologies. Playco's focus on seamless multiplayer interactions positions it as a leader in the evolution of social gaming.

Keatext Inc. is a Montreal-based company founded in 2010 that specializes in AI-powered text analytics. It offers a cloud-based platform designed to synthesize and analyze customer feedback from various sources, including surveys, online reviews, chat logs, and social media. By utilizing deep learning and natural language processing, Keatext enables businesses to uncover actionable insights from large volumes of unstructured data. The platform helps organizations understand customer sentiment and intent, allowing them to respond effectively to customer needs. With its comprehensive dashboard, Keatext aims to enhance customer experience management and foster meaningful relationships between businesses and their clients.

Mekonos Inc. is a biotechnology company founded in 2017 and based in San Francisco, California, specializing in the design, development, and production of gene and cell therapies. The company has created a proprietary cell-engineering platform that utilizes a silicon chip automated architecture to advance the field of genome editing. This innovative system-on-a-chip technology allows for the precise control of individual nanoneedles to inject single cells in a parallel architecture, enabling the industrial-scale production of engineered therapies for a range of genetic diseases, including cancers. Mekonos aims to provide healthcare providers with a reliable and reusable manufacturing system that can deliver various therapeutic molecules across different primary cell types, thus enhancing drug discovery and development processes.

UpLift, Inc. is a fintech company based in Menlo Park, California, founded in 2011. The company specializes in digital lending solutions for the travel industry, offering buy now, pay later services that allow consumers to finance their travel bookings through flexible payment plans. UpLift partners with over 100 leading travel brands to provide personalized payment options, enabling customers to budget more effectively while enhancing their travel experiences. By facilitating payments in monthly installments, UpLift aims to make travel more accessible and affordable, thereby increasing conversion rates and customer loyalty for its merchant partners.

Persist AI is a company that aids pharmaceutical firms in the development of long-acting drug formulations by leveraging artificial intelligence and automation. Traditional formulation development is a lengthy process, typically spanning 5 to 10 years, which includes extensive pre-clinical and clinical testing phases. Persist AI aims to significantly reduce this timeline by streamlining pre-clinical formulation development to just three months, enhancing the efficiency of the drug development process by 50%. The company employs AI-driven automation technologies, such as automated drug release testing and high-throughput formulation screening, to facilitate quicker and more reliable drug formulation. By doing so, Persist AI not only accelerates drug development but also contributes to improving patient outcomes.